Pavel Gershkovich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8682322/publications.pdf

Version: 2024-02-01

90 papers	2,256 citations	201674 27 h-index	254184 43 g-index
92 all docs	92 docs citations	92 times ranked	2751 citing authors

#	Article	IF	Citations
1	Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers. Pharmaceutics, 2022, 14, 270.	4.5	5
2	Is oral lipid-based delivery for drug targeting to the brain feasible?. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 112-122.	4.3	8
3	Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 174, 29-34.	4.3	10
4	Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. International Journal of Pharmaceutics, 2022, 624, 121947.	5.2	7
5	Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. Journal of Controlled Release, 2021, 329, 1077-1089.	9.9	25
6	Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate. Molecules, 2021, 26, 233.	3.8	0
7	Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus. Viruses, 2021, 13, 234.	3.3	33
8	Development and optimisation of simulated salivary fluid for biorelevant oral cavity dissolution. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 160, 125-133.	4.3	10
9	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 2021, 214, 113244.	5.5	10
10	Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 162, 43-49.	4.3	19
11	Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes. International Journal of Pharmaceutics, 2021, 602, 120621.	5.2	8
12	Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. ACS Applied Materials & Interfaces, 2021, 13, 35266-35280.	8.0	15
13	Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. Pharmaceutics, 2021, 13, 1349.	4.5	9
14	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 106-112.	4.3	0
15	Assessing Lymphatic Uptake of Lipids Using Magnetic Resonance Imaging: A Feasibility Study in Healthy Human Volunteers with Potential Application for Tracking Lymph Node Delivery of Drugs and Formulation Excipients. Pharmaceutics, 2021, 13, 1343.	4.5	0
16	Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin. Virulence, 2021, 12, 2946-2956.	4.4	12
17	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. ACS Medicinal Chemistry Letters, 2020, 11, 316-321.	2.8	3
18	Is rat a good model for assessment of particulate-based taste-masked formulations?. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 146, 1-9.	4.3	5

#	Article	IF	Citations
19	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical Pharmacokinetics, 2020, 59, 1493-1500.	3.5	31
20	Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate. Applied Sciences (Switzerland), 2020, 10, 7283.	2.5	5
21	Development and validation of a costâ€effective and sensitive bioanalytical HPLCâ€UV method for determination of lopinavir in rat and human plasma. Biomedical Chromatography, 2020, 34, e4934.	1.7	6
22	Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage. ACS Applied Materials & Interfaces, 2020, 12, 12609-12617.	8.0	24
23	Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. Journal of Controlled Release, 2020, 323, 549-564.	9.9	13
24	Abstract 1727: Challenging resistance to temozolomide in glioblastoma by drug encapsulation in apoferritin. , 2020, , .		0
25	Targeting brain tumours: apoferritin nanocage for delivery of novel analogues of temozolomide. Neuro-Oncology, 2019, 21, iv4-iv4.	1.2	1
26	A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin. Scientific Reports, 2019, 9, 15760.	3.3	17
27	Solid lipid nanoparticles self-assembled from spray dried microparticles. International Journal of Pharmaceutics, 2019, 572, 118784.	5.2	8
28	Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition. Cancer Letters, 2019, 453, 57-73.	7.2	37
29	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. Journal of Pharmacological Sciences, 2019, 139, 65-71.	2.5	1
30	Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine. International Journal of Pharmaceutics, 2019, 555, 228-236.	5.2	15
31	Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined InÂVitro Lipolysis/Microsomal Metabolism Approach. Journal of Pharmaceutical Sciences, 2019, 108, 1047-1052.	3.3	7
32	In search of effective therapies to overcome resistance to Temozolomide in brain tumours. , 2019, 2, 1018-1031.		7
33	Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation. Molecular Pharmaceutics, 2018, 15, 1578-1586.	4.6	3
34	Analytical ultracentrifugation in saliva research: Impact of green tea astringency and its significance on the in-vivo aroma release. Scientific Reports, 2018, 8, 13350.	3.3	8
35	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. Journal of Controlled Release, 2018, 286, 10-19.	9.9	41
36	Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 38-42.	4.3	61

#	Article	IF	Citations
37	Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. European Journal of Pharmaceutical Sciences, 2017, 100, 163-175.	4.0	7
38	Development of Cordycepin Formulations for Preclinical and Clinical Studies. AAPS PharmSciTech, 2017, 18, 3219-3226.	3.3	16
39	Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Scientific Reports, 2017, 7, 14542.	3.3	93
40	Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1040, 73-80.	2.3	16
41	Targeting Immunomodulatory Agents to the Gut-Associated Lymphoid Tissue. , 2016, , 237-261.		5
42	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 659-664.	1.6	8
43	Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations. Molecular Pharmaceutics, 2016, 13, 3526-3540.	4.6	14
44	The role of acid-base imbalance in statin-induced myotoxicity. Translational Research, 2016, 174, 140-160.e14.	5.0	28
45	Smart Lipid-Based Drug Delivery Systems. , 2016, , 309-371.		2
46	In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B. Cancer Letters, 2016, 370, 185-197.	7.2	41
47	Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research (discontinued), 2016, 8, 3448-59.	0.0	47
48	Lipid-lowering Activity of Natural and Semi-Synthetic Sterols and Stanols. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 344.	2.1	24
49	Development of a simple and sensitive HPLCâ€“UV method for the simultaneous determination of cannabidiol and Î”9-tetrahydrocannabinol in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 145-151.	2.8	56
50	Chain length affects pancreatic lipase activity and the extent and pHâ€“time profile of triglyceride lipolysis. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 353-362.	4.3	56
51	Characterisation of human saliva as a platform for oral dissolution medium development. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 91, 16-24.	4.3	108
52	Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Drug Development and Industrial Pharmacy, 2015, 41, 1425-1430.	2.0	9
53	Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs in Context, 2015, 4, 1-6.	2.2	7
54	Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Translational Research, 2014, 164, 85-109.	5.0	46

#	Article	IF	Citations
55	Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. Pharmaceutical Research, 2014, 31, 35-45.	3.5	37
56	Dissolution methodology for taste masked oral dosage forms. Journal of Controlled Release, 2014, 173, 32-42.	9.9	64
57	The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Drug Development and Industrial Pharmacy, 2014, 40, 1429-1434.	2.0	18
58	A simple and sensitive method for determination of vitamins D3and K1in rat plasma: application for anin vivopharmacokinetic study. Drug Development and Industrial Pharmacy, 2014, 40, 338-344.	2.0	15
59	Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats. Drug Development and Industrial Pharmacy, 2013, 39, 1277-1283.	2.0	16
60	Evaluation of the effect of plant sterols on the intestinal processing of cholesterol using an in vitro lipolysis model. International Journal of Pharmaceutics, 2012, 436, 707-710.	5.2	7
61	Inhibition of Cholesterol Absorption: Targeting the Intestine. Pharmaceutical Research, 2012, 29, 3235-3250.	3.5	15
62	Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. International Journal of Pharmaceutics, 2012, 436, 318-323.	5.2	11
63	Long-circulating non-toxic blood pool imaging agent based on hyperbranched polyglycerols. International Journal of Pharmaceutics, 2012, 422, 418-427.	5.2	38
64	Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. European Journal of Pharmaceutical Sciences, 2012, 46, 323-328.	4.0	26
65	Assessment of Cholesterol Absorption Inhibitors Nanostructured Aluminosilicate and Cholestyramine Using In Vitro Lipolysis Model. Journal of Pharmaceutical Sciences, 2012, 101, 291-300.	3.3	13
66	Simultaneous Determination of A Novel Antitrypanosomal Compound (OSU-36) and its Ester Derivative (OSU-40) in Plasma by HPLC: Application to First Pharmacokinetic Study in Rats. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 36.	2.1	4
67	Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (FungizoneÂ®): Pooled Analysis of Published Data. AAPS Journal, 2011, 13, 255-64.	4.4	23
68	Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids in Health and Disease, 2011, 10, 135.	3.0	26
69	In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines. Lipids in Health and Disease, 2011, 10, 144.	3.0	12
70	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation. Bioorganic and Medicinal Chemistry, 2011, 19, 513-523.	3.0	32
71	The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. Journal of Pharmacy and Pharmacology, 2010, 61, 31-39.	2.4	32
72	Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). Journal of Antimicrobial Chemotherapy, 2010, 65, 2610-2613.	3.0	28

#	Article	IF	Citations
73	Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. Journal of Antimicrobial Chemotherapy, 2010, 65, 535-537.	3.0	20
74	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Journal of Antimicrobial Chemotherapy, 2010, 65, 599-599.	3.0	0
75	A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model. PLoS Neglected Tropical Diseases, 2010, 4, e913.	3.0	51
76	Effect of hypertriglyceridemia on the pharmacokinetics and bloodâ€“brain barrier penetration of clozapine and norclozapine following administration to rats. European Neuropsychopharmacology, 2010, 20, 545-552.	0.7	9
77	Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds. Journal of Pharmaceutical Sciences, 2009, 98, 2390-2400.	3.3	23
78	Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. International Journal of Pharmaceutics, 2009, 372, 76-84.	5.2	105
79	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. Journal of Antimicrobial Chemotherapy, 2009, 64, 101-108.	3.0	76
80	Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. Translational Research, 2009, 153, 296-300.	5.0	4
81	Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet. Lipids in Health and Disease, 2009, 8, 30.	3.0	14
82	Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis. Journal of Infectious Diseases, 2009, 200, 357-360.	4.0	79
83	The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. Journal of Pharmacy and Pharmacology, 2009, 61, 31-39.	2.4	10
84	A Review of the Application of Lipid-Based Systems in Systemic, Dermal/ Transdermal, and Ocular Drug Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2008, 25, 545-584.	2.2	49
85	The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 759-765.	4.3	89
86	Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 839-844.	2.4	7
87	The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. International Journal of Pharmaceutics, 2007, 333, 1-4.	5.2	19
88	Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: Dexanabinol and PRS-211,220. European Journal of Pharmaceutical Sciences, 2007, 31, 298-305.	4.0	42
89	Effect of a high-fat meal on absorption and disposition of lipophilic compounds: The importance of degree of association with triglyceride-rich lipoproteins. European Journal of Pharmaceutical Sciences, 2007, 32, 24-32.	4.0	78
90	Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. European Journal of Pharmaceutical Sciences, 2005, 26, 394-404.	4.0	116